|
Apr 4
|
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug
|
|
Apr 3
|
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
|
|
Apr 3
|
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
|
|
Apr 3
|
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
|
|
Apr 2
|
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
|
|
Apr 2
|
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
|
|
Apr 2
|
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
|
|
Apr 2
|
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
|
|
Apr 1
|
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
|
|
Apr 1
|
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
|
|
Apr 1
|
Investors in ADMA Biologics (NASDAQ:ADMA) have seen splendid returns of 261% over the past three years
|
|
Apr 1
|
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
|
|
Mar 28
|
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
|
|
Mar 27
|
Praxis (PRAX) Surges on Positive Epilepsy Study Results
|
|
Mar 27
|
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
|
|
Mar 26
|
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
|
|
Mar 26
|
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
|
|
Mar 26
|
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
|
|
Mar 22
|
Why the Market Dipped But Adma Biologics (ADMA) Gained Today
|
|
Mar 22
|
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
|